ArticleImmunoHorizons2026
Semaphorin 3E regulates the response of regulatory T cells to lipopolysaccharide-induced systemic inflammation.
Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sepsis is a life-threatening systemic inflammation marked by an initial hyperinflammatory phase. Tregs are pivotal in tempering this early immune response. Semaphorins, originally neuronal guidance cues, have emerged as immune modulators. Notably, Sema3E influences dendritic cell and T cell responses, but its role in Treg-mediated regulation during endotoxemia is unclear. WT and Sema3e-/- mice were subjected to LPS-induced endotoxemia. Treg frequencies, proliferation and migration were assessed by flow cytometry and Transwell assays, respectively. Serum cytokines (eg IL-10) were quantified using ELISA. A TNFRSF25 agonist was administered to expand Tregs in vivo, and adoptive transfers of WT or Sema3e-/- Tregs were performed. Clinical scores and survival were recorded. Sema3e-/- mice exhibited significantly impaired Treg expansion and proliferation, altered migratory patterns with reduced Treg accumulation in spleen and lymph nodes, and consequently lower serum cytokine levels (eg IFN-γ) compared to WT, correlating with exacerbated disease severity. DR3-mediated Treg expansion in Sema3e-/- mice did not improve their clinical outcomes. Furthermore, adoptively transferred Sema3e-/- Tregs failed to confer protection in endotoxemic recipients, unlike WT Tregs. Sema3E is essential for optimal Treg responses and immune regulation during severe LPS-induced inflammation. Its absence compromises Treg expansion, localization, and function, worsening sepsis outcomes. These findings highlight Sema3E as a critical component of Treg-mediated immunosuppression and a potential therapeutic target for improving immune homeostasis in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.